**Specifications table**TableSubject areaToxicologyMore specific subject areaGeneral toxicity effectType of dataTables, figuresHow data were acquiredRat toxicity test data were collected according to the M3 guidelines developed by ICH for non-clinical repeated dose toxicity. Measurements of arsenic metabolites and accumulation were performed on an Agilent 7700ce ICP-MS instrument coupled with the Agilent 1200 Series HPLC system.Data formatRaw and analysedExperimental factorsTo analyze the short-term toxicity of realgar, rats were treated with different doses of realgar for 30 days. Then, the function and tissue structure changes of the whole-body organs of the rats were tested. Analysis of total arsenic (tAs) and arsenic (As) in rat blood and organs using the Agilent 7700ce ICP-MS instrument and the Agilent 1200 Series HPLC system.Experimental featuresStudies were performed under GLP conditions according the current OECD Test guideline TG407 "Repeated Dose 28-Day oral Toxicity Study in Rodents". Comparison of various arsenic species accumulation and distribution.Data source locationInstitute of Chinese Materia Medica, China Academy of Chinese Medical Sciences, Beijing, ChinaData accessibilityData available within the article.Related research articleYi, Y., Gao, S., Xia, J., Li, C., Zhao, Y., Zhang, Y., Liang A., Ji S. Study of the accumulation and distribution of arsenic species and association with arsenic toxicity in rats after 30 days of oral realgar administration. Journal of Ethnopharmacology. 2019, 11576 [@bib1].

**Value of the data**•The data show the repeated-dose 30-day oral toxicity of realgar in rats, which provides a reference for the safe dose range for repeated oral administration of realgar for 2 weeks in humans.•The accumulation and distribution of arsenic species in rat tissues not only helps in understanding the metabolism of arsenic in animals but also helps elucidate the main arsenic-accumulating organs in the body.•The total arsenic content is not sufficient for the safety evaluation of realgar. The data revealed a possible link between arsenic species and the sub-chronic toxicity of realgar, which can help people study the toxicity of realgar more scientifically and find reasonable prevention and treatment.

1. Data {#s0005}
=======

The content of arsenic species in rats after a single administration of realgar is shown in [Table 1](#t0005){ref-type="table"}, [Table 2](#t0010){ref-type="table"}, [Table 3](#t0015){ref-type="table"}, [Table 4](#t0020){ref-type="table"}, [Table 5](#t0025){ref-type="table"}. The body weights ([Table 6](#t0030){ref-type="table"}, [Table 7](#t0035){ref-type="table"}, [Table 8](#t0040){ref-type="table"}), haematology, electrolytes, coagulation ([Table 9](#t0045){ref-type="table"}, [Table 10](#t0050){ref-type="table"}), biochemical parameters ([Table 11](#t0055){ref-type="table"}, [Table 12](#t0060){ref-type="table"}) and relative organ weights ([Table 13](#t0065){ref-type="table"}, [Table 14](#t0070){ref-type="table"}) of male and female rats after 30 days of administration of realgar are shown below. In addition, the content of arsenic species in the rats is shown in [Table 15](#t0075){ref-type="table"}, [Table 16](#t0080){ref-type="table"}, [Table 17](#t0085){ref-type="table"}.Table 1Content of arsenic species in the livers of rats from 0 h to 48 h after a single administration of realgar (n = 6, 3 males and 3 females per group, $\overline{x}$ ± SD).Table 1TimeAsCAsBAs(III)DMAMMAAs(V)tAs0 h0.00 ± 0.000.03 ± 0.010.00 ± 0.000.28 ± 0.040.02 ± 0.020.03 ± 0.050.82 ± 0.290.25 h0.00 ± 0.000.04 ± 0.012.54 ± 1.33^\*^0.67 ± 0.380.34 ± 0.140.12 ± 0.04^\*\*^5.16 ± 1.91^\*\*^0.5 h0.00 ± 0.000.02 ± 0.014.03 ± 1.91^\*\*^0.63 ± 0.26^\*^0.49 ± 0.12^\*^0.27 ± 0.11^\*\*\*^7.55 ± 1.82^\*\*^1 h0.00 ± 0.000.02 ± 0.012.58 ± 0.98^\*\*^0.91 ± 0.990.49 ± 0.14^\*\*^0.16 ± 0.04^\*\*\*^6.72 ± 2.34^\*\*^2 h0.00 ± 0.000.02 ± 0.012.62 ± 1.48^\*\*^1.51 ± 0.36^\*\*^0.44 ± 0.23^\*^0.12 ± 0.08^\*^6.98 ± 2.79^\*\*^4 h0.00 ± 0.000.03 ± 0.010.89 ± 0.31^\*\*^1.52 ± 0.17^\*\*^0.17 ± 0.060.10 ± 0.05^\*^5.18 ± 0.71^\*\*^8 h0.00 ± 0.000.02 ± 0.010.30 ± 0.04^\*\*^1.86 ± 0.17^\*^0.06 ± 0.060.05 ± 0.054.14 ± 0.73^\*\*^16 h0.00 ± 0.000.02 ± 0.010.20 ± 0.04^\*^2.58 ± 0.17^\*\*^0.03 ± 0.030.03 ± 0.044.30 ± 0.82^\*\*^32 h0.00 ± 0.000.04 ± 0.020.07 ± 0.04^\*^1.74 ± 0.28^\*\*^0.01 ± 0.020.03 ± 0.032.93 ± 0.73^\*^48 h0.00 ± 0.000.03 ± 0.010.06 ± 0.04^\*^1.39 ± 0.89^\*\*^0.02 ± 0.010.04 ± 0.062.09 ± 1.17^\*^[^1]Table 2Content of arsenic species in the kidneys of rats from 0 h to 48 h after a single administration of realgar (*n* = 6, 3 males and 3 females per group, $\overline{x}$ ± SD).Table 2TimeAsCAsBAs(III)DMAMMAAs(V)tAs0 h0.00 ± 0.000.00 ± 0.000.07 ± 0.020.11 ± 0.050.00 ± 0.000.19 ± 0.070.38 ± 0.280.25 h0.00 ± 0.000.00 ± 0.001.32 ± 0.66^\*^0.22 ± 0.05^\*^0.19 ± 0.11^\*^1.72 ± 0.76^\*\*^2.50 ± 1.31^\*\*^0.5 h0.00 ± 0.000.00 ± 0.003.32 ± 1.41^\*\*^0.24 ± 0.06^\*^0.38 ± 0.08^\*\*^3.98 ± 1.39^\*\*\*^6.77 ± 2.86^\*\*\*^1 h0.00 ± 0.000.00 ± 0.001.60 ± 1.13^\*\*^0.29 ± 0.12^\*^0.40 ± 0.26^\*\*^2.32 ± 1.45^\*\*^3.64 ± 1.94^\*\*^2 h0.00 ± 0.000.00 ± 0.002.46 ± 1.120.54 ± 0.07^\*\*^0.74 ± 0.30^\*\*^3.76 ± 1.34^\*\*\*^8.61 ± 5.01^\*\*\*^4 h0.00 ± 0.000.00 ± 0.000.53 ± 0.27^\*\*^0.60 ± 0.10^\*\*^0.31 ± 0.13^\*\*^1.45 ± 0.47^\*\*^2.27 ± 0.69^\*\*^8 h0.00 ± 0.000.00 ± 0.000.18 ± 0.08^\*\*^0.57 ± 0.06^\*\*^0.16 ± 0.05^\*\*^0.92 ± 0.12^\*\*^1.57 ± 0.33^\*\*^16 h0.00 ± 0.000.00 ± 0.000.15 ± 0.03^\*\*^0.54 ± 0.12^\*\*^0.19 ± 0.12^\*^0.87 ± 0.25^\*\*^1.78 ± 0.76^\*\*^32 h0.00 ± 0.000.00 ± 0.000.12 ± 0.04^\*^0.69 ± 0.13^\*\*^0.07 ± 0.08^\*^0.88 ± 0.22^\*\*^1.63 ± 0.75^\*\*^48 h0.00 ± 0.000.00 ± 0.000.13 ± 0.02^\*^0.82 ± 0.26^\*\*^0.21 ± 0.15^\*^1.16 ± 0.24^\*\*^2.03 ± 0.27^\*\*\*^[^2]Table 3Content of arsenic species in the brains of rats from 0 h to 48 h after a single administration of realgar (*n* = 6, 3 males and 3 females per group, $\overline{x}$ ± SD).Table 3TimeAsCAsBAs(III)DMAMMAAs(V)tAs0 h0.00 ± 0.000.00 ± 0.000.04 ± 0.020.06 ± 0.020.00 ± 0.000.56 ± 0.091.35 ± 0.300.25 h0.00 ± 0.000.00 ± 0.000.06 ± 0.020.08 ± 0.030.00 ± 0.000.64 ± 0.142.00 ± 0.29^\*\*^0.5 h0.00 ± 0.000.00 ± 0.000.08 ± 0.030.09 ± 0.030.00 ± 0.000.56 ± 0.071.71 ± 0.201 h0.00 ± 0.000.00 ± 0.000.07 ± 0.020.11 ± 0.030.00 ± 0.000.59 ± 0.061.90 ± 0.28^\*^2 h0.00 ± 0.000.00 ± 0.000.09 ± 0.050.19 ± 0.060.00 ± 0.000.57 ± 0.071.81 ± 0.21^\*^4 h0.00 ± 0.000.00 ± 0.000.09 ± 0.050.31 ± 0.07^\*\*^0.00 ± 0.000.56 ± 0.051.77 ± 0.308 h0.00 ± 0.000.00 ± 0.000.05 ± 0.010.44 ± 0.06^\*\*\*^0.00 ± 0.000.56 ± 0.062.01 ± 0.46^\*\*^16 h0.00 ± 0.000.00 ± 0.000.06 ± 0.010.43 ± 0.13^\*\*^0.00 ± 0.000.58 ± 0.051.87 ± 0.37^\*^32 h0.00 ± 0.000.00 ± 0.000.05 ± 0.010.43 ± 0.06^\*\*\*^0.00 ± 0.000.57 ± 0.092.17 ± 0.27^\*\*^48 h0.00 ± 0.000.00 ± 0.000.06 ± 0.020.40 ± 0.04^\*\*\*^0.00 ± 0.000.59 ± 0.102.05 ± 0.51^\*\*^[^3]Table 4Content of arsenic species in the plasma of rats from 0 h to 48 h after a single administration of realgar (*n* = 6, 3 males and 3 females per group, $\overline{x}$ ± SD).Table 4TimeAsCAsBAs(III)DMAMMAAs(V)tAs0 h0.00 ± 0.000.00 ± 0.000.00 ± 0.003.88 ± 0.060.00 ± 0.000.19 ± 0.034.06 ± 0.700.25 h0.00 ± 0.000.00 ± 0.000.00 ± 0.003.53 ± 0.270.00 ± 0.000.22 ± 0.023.73 ± 0.350.5 h0.00 ± 0.000.00 ± 0.000.00 ± 0.003.94 ± 1.460.00 ± 0.000.24 ± 0.044.24 ± 1.511 h0.00 ± 0.000.00 ± 0.000.00 ± 0.004.85 ± 1.230.00 ± 0.000.23 ± 0.045.20 ± 0.192 h0.00 ± 0.000.00 ± 0.000.00 ± 0.006.96 ± 2.41^\*^0.00 ± 0.000.23 ± 0.027.29 ± 2.42^\*^4 h0.00 ± 0.000.00 ± 0.000.00 ± 0.0011.85 ± 4.13^\*\*^0.00 ± 0.000.19 ± 0.0612.40 ± 4.29^\*\*^8 h0.00 ± 0.000.00 ± 0.000.00 ± 0.0018.80 ± 4.50^\*\*\*^0.00 ± 0.000.19 ± 0.0219.05 ± 4.28^\*\*\*^16 h0.00 ± 0.000.00 ± 0.000.00 ± 0.0031.75 ± 4.33^\*\*\*^0.00 ± 0.000.13 ± 0.0931.60 ± 4.25^\*\*\*^32 h0.00 ± 0.000.00 ± 0.000.00 ± 0.0026.95 ± 0.61^\*\*\*^0.00 ± 0.000.18 ± 0.0227.10 ± 4.87^\*\*\*^48 h0.00 ± 0.000.00 ± 0.000.00 ± 0.0035.70 ± 5.11^\*\*\*^0.00 ± 0.000.20 ± 0.0235.95 ± 5.14^\*\*\*^[^4]Table 5Content of arsenic species in the urine of rats from 0 h to 48 h after a single administration of realgar (*n* = 6, 3 males and 3 females per group, $\overline{x}$ ± SD).Table 5Arsenic speciesControl0--12 h12--24 hAsC0.00 ± 0.000.00 ± 0.000.00 ± 0.00AsB0.00 ± 0.000.01 ± 0.000.01 ± 0.01As(III)0.00 ± 0.000.47 ± 0.14^\*^0.09 ± 0.10^\*^DMA0.00 ± 0.003.19 ± 0.18^\*\*\*^1.01 ± 0.59^\*^MMA0.00 ± 0.000.71 ± 0.06^\*\*^0.28 ± 0.28As(V)0.00 ± 0.000.42 ± 0.020.11 ± 0.11t-As0.00 ± 0.0010.30 ± 0.33^\*\*\*^3.48 ± 0.51^\*\*\*^[^5]Table 6Body weights of male rats after treatment with realgar at 170 mg/kg for 30 days (*n* = 5, $\overline{x}$ ± SD).Table 6TimeControlRealgar10.6 mg/kg40.5 mg/kg170 mg/kg0 d236.15 ± 11.01236.00 ± 11.77234.64 ± 11.65235.48 ± 13.348 d280.64 ± 16.24284.06 ± 13.76281.99 ± 14.99284.11 ± 15.1215 d326.56 ± 23.67331.36 ± 18.18328.18 ± 17.69329.03 ± 19.8222 d346.47 ± 28.63351.55 ± 21.62349.32 ± 20.06345.97 ± 22.0029 d390.89 ± 32.97385.82 ± 22.96387.12 ± 28.14379.35 ± 35.60[^6]Table 7Body weights of female rats after treatment with realgar at 170 mg/kg for 30 days (*n* = 5, $\overline{x}$ ± SD).Table 7TimeControlRealgar10.6 mg/kg40.5 mg/kg170 mg/kg0 d182.64 ± 10.40181.67 ± 12.32182.65 ± 10.50182.75 ± 10.208 d204.94 ± 10.62203.50 ± 13.53202.33 ± 10.66205.83 ± 12.7815 d218.84 ± 12.35222.83 ± 18.72221.51 ± 11.78223.68 ± 13.9922 d231.82 ± 13.84230.12 ± 20.79229.27 ± 13.44237.42 ± 13.8829 d248.26 ± 16.50240.21 ± 30.77242.82 ± 22.68246.71 ± 20.75[^7]Table 8Haematological data from the oral administration of realgar for 30 days in male rats (*n* = 5, $\overline{x}$ ± SD).Table 8ItemControlRealgar10.6 mg/kg40.5 mg/kg170 mg/kg**WBC (10**^**9**^**/L)**4.09 ± 0.455.60 ± 1.365.49 ± 1.43^\*^5.20 ± 1.15^\*^**RBC (10**^**12**^**/L)**7.09 ± 0.327.05 ± 0.517.52 ± 0.25^\*^7.53 ± 0.42**HGB (g/L)**127.00 ± 5.48128.20 ± 6.53130.60 ± 3.78135.40 ± 7.64^\*^**HCT (%)**39.72 ± 1.4739.52 ± 2.0740.20 ± 1.2041.72 ± 2.13**MCV (fL)**56.02 ± 1.4456.12 ± 1.4653.48 ± 1.22^\*\*^55.44 ± 0.35**MCH (pg)**17.88 ± 0.5018.24 ± 0.4717.36 ± 0.4017.96 ± 0.15**MCHC (g/L)**319.20 ± 5.31324.80 ± 4.55324.60 ± 2.07^\*^324.40 ± 3.05^\*^**PLT (10**^**9**^**/L)**1202.20 ± 112.521251.40 ± 178.271323.00 ± 119.521192.60 ± 111.39**Gr (%)**70.80 ± 5.8578.82 ± 4.84^\*^82.90 ± 1.80^\*\*^79.20 ± 3.12^\*^**Ly (%)**4.58 ± 0.913.02 ± 0.7392.32 ± 0.562.66 ± 0.69**MO (%)**24.62 ± 5.4218.16 ± 4.59^\*^14.44 ± 1.71^\*\*^17.78 ± 2.69^\*^**PT (S)**12.20 ± 0.5812.58 ± 0.4212.68 ± 0.4010.98 ± 4.15**APTT (S)**19.20 ± 1.3117.60 ± 1.36^\*^20.32 ± 1.5818.26 ± 3.15[^8]Table 9Haematological data from the oral administration of realgar for 30 days in female rats (*n* = 5, $\overline{x}$ ± SD).Table 9ItemControlRealgar10.6 mg/kg40.5 mg/kg170 mg/kg**WBC (10**^**9**^**/L)**2.51 ± 0.353.75 ± 1.353.40 ± 0.97^\*^3.17 ± 0.96**RBC (10**^**12**^**/L)**6.47 ± 0.296.71 ± 0.276.66 ± 0.206.82 ± 0.19^\*^**HGB (g/L)**114.00 ± 4.30119.80 ± 4.49^\*^120.60 ± 3.71^\*^120.80 ± 3.11^\*^**HCT (%)**35.62 ± 1.0136.62 ± 1.3336.52 ± 1.0536.72 ± 0.59^\*^**MCV (fL)**55.10 ± 1.0154.56 ± 1.6854.86 ± 1.5353.90 ± 1.59**MCH (pg)**17.66 ± 0.5117.84 ± 0.6118.14 ± 0.5617.76 ± 0.44**MCHC (g/L)**320.00 ± 6.36326.80 ± 1.48^\*^330.40 ± 2.07^\*\*^329.20 ± 4.82^\*^**PLT (10**^**9**^**/L)**1111.80 ± 119.291041.40 ± 86.511128.00 ± 41.841218.60 ± 85.36**Gr (%)**76.42 ± 4.7480.40 ± 7.4481.12 ± 5.1979.00 ± 7.39**Ly (%)**3.04 ± 0.985.62 ± 6.883.46 ± 0.953.84 ± 1.00**MO (%)**20.04 ± 4.6213.58 ± 8.1415.06 ± 5.5016.72 ± 6.70**PT (S)**13.16 ± 0.5113.62 ± 0.3013.48 ± 0.4111.43 ± 4.75**APTT (S)**21.62 ± 2.0421.64 ± 3.7619.62 ± 2.2918.96 ± 2.25^\*^[^9]Table 10Serum biochemistry data from the oral administration of realgar for 30 days in male rats (*n* = 5, $\overline{x}$ ± SD).Table 10ItemControlRealgar10.6 mg/kg40.5 mg/kg170 mg/kg**ALB (g/L)**32.74 ± 1.2832.30 ± 3.4731.52 ± 0.7432.12 ± 1.38**ALP (IU)**118.80 ± 16.10105.20 ± 13.26110.00 ± 10.2794.60 ± 5.18^\*^**ALT (U/L)**36.60 ± 4.9833.40 ± 4.8330.60 ± 3.13^\*^31.60 ± 5.86**AST (U/L)**113.20 ± 23.13137.80 ± 20.8694.00 ± 7.35128.00 ± 10.56**T-CHO (mmol/L)**1.91 ± 0.1832.30 ± 3.4731.52 ± 0.7432.12 ± 1.38**CK-NAC (U/L)**378.00 ± 168.30181.00 ± 120.66^\*^565.20 ± 98.01^\*^379.80 ± 46.24**CRE (µmol/L)**45.60 ± 1.6744.20 ± 1.3047.80 ± 1.64^\*^45.60 ± 2.51**γ-GT (U/L)**0.34 ± 0.180.22 ± 0.180.20 ± 0.140.24 ± 0.09**GLU (mmol/L)**5.89 ± 0.187.84 ± 0.52^\*\*\*^7.88 ± 0.49^\*\*\*^7.39 ± 0.25^\*\*\*^**BUN (mmol/L)**5.92 ± 0.265.00 ± 0.48^\*\*^5.14 ± 0.38^\*\*^5.92 ± 0.70**TBIL (µmol/L)**4.48 ± 0.894.70 ± 0.657.88 ± 3.06^\*^5.00 ± 0.75**TG (mmol/L)**0.46 ± 0.110.38 ± 0.090.37 ± 0.050.39 ± 0.18**TP (g/L)**55.28 ± 2.7052.46 ± 0.96^\*^54.24 ± 3.9352.26 ± 2.47**Na (mmol/L)**143.32 ± 5.72140.30 ± 1.38138.90 ± 0.84140.18 ± 1.38**K (mmol/L)**4.44 ± 0.433.93 ± 0.40^\*^5.02 ± 0.52^\*^4.38 ± 0.16**Cl (mmol/L)**109.16 ± 4.67108.06 ± 1.78108.56 ± 0.39108.30 ± 1.41[^10]Table 11Serum biochemistry data from the oral administration of realgar for 30 days in female rats (*n* = 5, $\overline{x}$ ± SD).Table 11ItemControlRealgar10.6 mg/kg40.5 mg/kg170 mg/kg**ALB (g/L)**32.24 ± 2.3829.30 ± 0.53^\*^29.06 ± 1.25^\*^30.34 ± 1.17**ALP (IU)**54.40 ± 10.3872.40 ± 18.72^\*\*^63.80 ± 14.0260.80 ± 14.08**ALT (U/L)**33.20 ± 6.3036.00 ± 4.4225.00 ± 3.08^\*^25.80 ± 3.77^\*^**AST (U/L)**118.20 ± 13.03111.60 ± 13.67113.20 ± 13.88112.20 ± 30.44**T-CHO (mmol/L)**1.42 ± 0.311.19 ± 0.181.21 ± 0.211.30 ± 0.16**CK-NAC (U/L)**348.00 ± 135.51318.60 ± 87.27371.40 ± 55.56457.00 ± 239.78**CRE (µmol/L)**51.80 ± 2.2848.00 ± 4.85^\*\*^47.00 ± 4.64^\*^49.20 ± 5.22**γ-GT (U/L)**0.46 ± 0.170.46 ± 0.090.44 ± 0.250.60 ± 0.10**GLU (mmol/L)**6.46 ± 0.496.65 ± 0.386.62 ± 0.486.15 ± 0.51**BUN (mmol/L)**7.05 ± 1.027.55 ± 2.075.44 ± 0.58^\*\*^6.17 ± 1.54**TBIL (µmol/L)**3.14 ± 0.323.32 ± 0.702.70 ± 0.503.32 ± 0.67**TG (mmol/L)**0.25 ± 0.030.27 ± 0.060.24 ± 0.030.32 ± 0.03^\*\*^**TP (g/L)**52.32 ± 2.8048.38 ± 0.9148.24 ± 1.51^\*^50.12 ± 2.10**Na (mmol/L)**140.72 ± 1.41141.30 ± 0.74138.34 ± 3.57139.72 ± 1.30**K (mmol/L)**3.72 ± 0.294.23 ± 0.52^**\***^3.79 ± 0.183.74 ± 0.11**Cl (mmol/L)**109.90 ± 1.88110.82 ± 1.47108.14 ± 2.88109.32 ± 0.79[^11]Table 12Relative organ weights data from the oral administration of realgar for 30 days in male rats (%).Table 12ItemControlRealgar10.6 mg/kg40.5 mg/kg170 mg/kg**Heart**0.323 ± 0.0330.334 ± 0.0200.311 ± 0.0220.317 ± 0.020**Liver**2.952 ± 0.2473.012 ± 0.1203.082 ± 0.1982.514 ± 0.860**Spleen**0.250 ± 0.0300.230 ± 0.1670.235 ± 0.0160.269 ± 0.037**Lung**0.415 ± 0.0460.429 ± 0.0430.433 ± 0.0330.435 ± 0.028**Kidney**0.746 ± 0.0340.686 ± 0.1640.728 ± 0.0350.730 ± 0.061**Brain**0.522 ± 0.0340.560 ± 0.0440.544 ± 0.0260.551 ± 0.058**Stomach**0.018 ± 0.0030.020 ± 0.0030.020 ± 0.0030.018 ± 0.004**Adrenal gland**0.376 ± 0.1200.401 ± 0.0920.352 ± 0.0850.389 ± 0.099**Thymus**0.944 ± 0.0670.778 ± 0.4350.902 ± 0.1441.035 ± 0.058**Testis**0.256 ± 0.0860.211 ± 0.0350.194 ± 0.017^\*^0.230 ± 0.048**Epididymis**0.205 ± 0.0560.182 ± 0.0200.170 ± 0.0740.162 ± 0.060[^12]Table 13Relative organ weights data from the oral administration of realgar for 30 days in female rats (%).Table 13ItemControlRealgar10.6 mg/kg40.5 mg/kg170 mg/kg**Heart**0.355 ± 0.0160.369 ± 0.0480.370 ± 0.0380.371 ± 0.026**Liver**3.083 ± 0.1063.124 ± 0.1322.774 ± 0.073^\*\*^2.798 ± 0.108^\*\*^**Spleen**0.314 ± 0.0270.275 ± 0.014^\*^0.285 ± 0.015^\*^0.323 ± 0.028**Lung**0.511 ± 0.0220.625 ± 0.1880.539 ± 0.0420.555 ± 0.024**Kidney**0.710 ± 0.0250.720 ± 0.0230.742 ± 0.0610.715 ± 0.025**Brain**0.826 ± 0.0400.770 ± 0.0550.811 ± 0.0720.895 ± 0.081**Stomach**0.038 ± 0.0070.035 ± 0.0070.042 ± 0.0060.042 ± 0.013**Adrenal gland**0.255 ± 0.1630.231 ± 0.0680.301 ± 0.0790.276 ± 0.040**Thymus**0.220 ± 0.3130.080 ± 0.0100.070 ± 0.0100.075 ± 0.010**Testis**0.396 ± 0.3730.245 ± 0.0540.228 ± 0.0330.251 ± 0.188[^13]Table 14Plasma arsenic species content in rats after oral administration of realgar for 30 days (*n* = 10, 5 males and 5 females per group, $\overline{x}$ ± SD).Table 14ItemControlRealgar10.6 mg/kg40.5 mg/kg170 mg/kg**As(III)**0.02 ± 0.020.02 ± 0.020.02 ± 0.020.02 ± 0.01**DMA**7.91 ± 0.7067.11 ± 2.29^\*\*\*^168.94 ± 8.92^\*\*\*^236.27 ± 8.05^\*\*\*^**MMA**0.02 ± 0.010.04 ± 0.010.02 ± 0.020.04 ± 0.03**As(V)**0.08 ± 0.050.04 ± 0.030.04 ± 0.030.03 ± 0.02**tAs**8.49 ± 0.5868.62 ± 2.66^\*\*\*^174.56 ± 10.98^\*\*\*^253.50 ± 23.33^\*\*\*^[^14]Table 15Liver arsenic species content in rats after oral administration of realgar for 30 days (*n* = 10, 5 males and 5 females per group, $\overline{x}$ ± SD).Table 15ItemControlRealgar10.6 mg/kg40.5 mg/kg170 mg/kg**AsC**0.004 ± 0.0020.005 ± 0.0030.005 ± 0.0020.004 ± 0.003**AsB**0.003 ± 0.0020.003 ± 0.0020.062 ± 0.0520.236 ± 0.128^\*^**As(III)**0.009 ± 0.0070.026 ± 0.0250.074 ± 0.0480.359 ± 0.122^\*\*^**DMA**0.959 ± 0.14510.321 ± 2.460^\*\*^23.099 ± 3.384^\*\*\*^31.678 ± 5.544^\*\*\*^**MMA**0.018 ± 0.0120.019 ± 0.0130.019 ± 0.0070.020 ± 0.014**As(V)**0.023 ± 0.010.029 ± 0.0140.024 ± 0.0120.021 ± 0.011**tAs**2.298 ± 0.37915.545 ± 2.518^\*\*^28.135 ± 4.833^\*\*\*^38.300 ± 7.788^\*\*\*^[^15]Table 16Kidney arsenic species content in rats after oral administration of realgar for 30 days (*n* = 10, 5 males and 5 females per group, $\overline{x}$ ± SD).Table 16ItemControlRealgar10.6 mg/kg40.5 mg/kg170 mg/kg**AsC**0.002 ± 0.0010.001 ± 0.0010.001 ± 0.0000.005 ± 0.007**AsB**0.003 ± 0.0010.003 ± 0.0010.002 ± 0.0000.006 ± 0.009**As(III)**0.047 ± 0.0060.055 ± 0.0080.066 ± 0.007^\*^0.250 ± 0.122^\*^**DMA**0.595 ± 0.1133.973 ± 0.750^\*\*\*^11.435 ± 0.635^\*\*\*^18.470 ± 3.007^\*\*^**MMA**0.004 ± 0.0040.121 ± 0.105^\*\*^0.987 ± 1.844^\*\*^7.626 ± 1.844^\*^**As(V)**0.015 ± 0.0110.011 ± 0.0100.024 ± 0.0150.441 ± 0.433**tAs**3.678 ± 0.55810.054 ± 2.813^\*\*^25.025 ± 7.365^\*\*^54.434 ± 15.210^\*^[^16]Table 17Brain arsenic species content in rats after oral administration of realgar for 30 days (*n* = 10, 5 males and 5 females per group, $\overline{x}$ ± SD).Table 17ItemControlRealgar10.6 mg/kg40.5 mg/kg170 mg/kg**AsC**0.001 ± 0.0000.001 ± 0.0010.001 ± 0.0000.002 ± 0.001**AsB**0.003 ± 0.0010.004 ± 0.0010.002 ± 0.0000.003 ± 0.003**As(III)**0.041 ± 0.0060.059 ± 0.008^\*^0.067 ± 0.009^\*\*^0.233 ± 0.073^\*^**DMA**0.08 ± 0.050.845 ± 0.153^\*\*^2.166 ± 0.222^\*\*\*^2.997 ± 0.347^\*\*\*^**MMA**0.02 ± 0.010.02 ± 0.010.03 ± 0.020.02 ± 0.01**As(V)**0.01 ± 0.010.02 ± 0.010.02 ± 0.010.02 ± 0.01**tAs**0.91 ± 0.181.80 ± 0.524.03 ± 1.075.70 ± 0.64[^17]

2. Experimental design, materials and methods {#s0010}
=============================================

2.1. Single administration of realgar and biological sample collection {#s0015}
----------------------------------------------------------------------

The rats were fasted for 16 h and then given a single realgar dose of 0 mg/kg (control) or 170 mg/kg (the realgar groups). Then, a blood sample was taken from the medial canthus vein of each mouse at 0.25, 0.5, 1, 2, 4, 8, 16, 32, and 48 h. Blood samples were anticoagulated and centrifuged to obtain plasma samples. Finally, rats were euthanized and their livers, kidneys and brains were removed.

2.2. Detection of the toxicity of realgar in rats after 30 days of oral administration [@bib2], [@bib3] {#s0020}
-------------------------------------------------------------------------------------------------------

In total, 40 rats were randomly and equally divided into 4 groups as follows: ① the control group; ② the realgar 10.6 mg/kg/d group; ③ the realgar 40.5 mg/kg/d group; and ④ the realgar 170 mg/kg/d group. All rats were orally administered either 0.3% carboxymethylcellulose sodium (CMC-Na) in ultra-pure water (control group) or realgar (realgar groups) once daily for 30 consecutive days. At 31 days, the rats were anaesthetized using an intraperitoneal injection of phenobarbital sodium. Blood samples were then collected from the abdominal aorta for haematology, coagulation, biochemical and electrolyte analyses. Finally, the rats were sacrificed, and all organs were excised, observed, and weighed.

2.3. Analysis of the accumulation and distribution of As species in biological samples [@bib4] {#s0025}
----------------------------------------------------------------------------------------------

An Agilent 7700ce ICP-MS instrument coupled with the Agilent 1200 Series HPLC system was used for quantitative analyses of the tAs and As species content in rats plasma and organs.
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[^1]: All values are expressed as the means (M) ± standard deviation (SD). ^\*^*p* \<0.05, ^\*\*^*p* \< 0.01, ^\*\*\*^*p* \< 0.001. Values are compared with the content at 0 h. Differences were analysed by a one-way analysis of variance.

[^2]: All values are expressed as the means (M) ± standard deviation (SD). ^\*^*p* \< 0.05, ^\*\*^*p* \< 0.01, ^\*\*\*^*p* \< 0.001. Values are compared with the content at 0 h. Differences were analysed by a one-way analysis of variance.

[^3]: All values are expressed as the means (M) ± standard deviation (SD). ^\*^*p* \< 0.05, ^\*\*^*p* \< 0.01, ^\*\*\*^*p* \< 0.001. Values are compared with the content at 0 h. Differences were analysed by a one-way analysis of variance.

[^4]: All values are expressed as the means (M) ± standard deviation (SD). ^\*^*p* \< 0.05, ^\*\*^*p* \< 0.01, ^\*\*\*^*p* \< 0.001. Values are compared with the content at 0 h. Differences were analysed by a one-way analysis of variance.

[^5]: All values are expressed as the means (M) ± standard deviation (SD). ^\*^*p* \< 0.05, ^\*\*^*p* \< 0.01, ^\*\*\*^*p* \< 0.001. Values are compared with the content at 0 h. Differences were analysed by a one-way analysis of variance.

[^6]: All values are expressed as the means (M) ± standard deviation (SD). ^\*^*p* \< 0.05, ^\*\*^*p* \< 0.01, ^\*\*\*^*p* \< 0.001. The body weights per time are compared to those of the control group. Differences were analysed by a one-way analysis of variance.

[^7]: All values are expressed as the means (M) ± standard deviation (SD). ^\*^*p* \< 0.05, ^\*\*^*p* \< 0.01, ^\*\*\*^*p* \< 0.001. The body weights per time are compared to those of the control group. Differences were analysed by a one-way analysis of variance.

[^8]: All values are expressed as the means (M) ± standard deviation (SD). ^\*^*p* \< 0.05, ^\*\*^*p* \< 0.01, ^\*\*\*^*p* \< 0.001. Values are compared with those of the control group. Differences were analysed by a one-way analysis of variance. WBC: white blood cells; RBC: red blood cells; HGB: haemoglobin; HCT: haematocrit; MCV: mean corpuscular volume; MCH: mean corpuscular haemoglobin; MCHC: mean corpuscular haemoglobin concentration; PLT: blood platelet number; GR%: neutrophilic granulocyte ratio; LY%: lymphocyte ratio; MO: monocytes ratio; PT: prothrombin time; APTT: activated partial thromboplastin time.

[^9]: All values are expressed as the means (M) ± standard deviation (SD). ^\*^*p* \< 0.05, ^\*\*^*p* \< 0.01, ^\*\*\*^*p* \< 0.001. Values are compared with those of the control group. Differences were analysed by a one-way analysis of variance. WBC: white blood cells; RBC: red blood cells; HGB: haemoglobin; HCT: haematocrit; MCV: mean corpuscular volume; MCH: mean corpuscular haemoglobin; MCHC: mean corpuscular haemoglobin concentration; PLT: blood platelet number; GR%: neutrophilic granulocyte ratio; LY%: lymphocyte ratio; MO: monocytes ratio; PT: prothrombin time; APTT: activated partial thromboplastin time.

[^10]: All values are expressed as the means (M) ± standard deviation (SD). ^\*^*p* \< 0.05, ^\*\*^*p* \< 0.01, ^\*\*\*^*p* \< 0.001. Values are compared with those of the control group. Differences were analysed by a one-way analysis of variance. ALB: total albumin; ALP: alkaline phosphatase; ALT: alanine aminotransferase; AST: aspartate aminotransferase; CHO: cholesterol; CK: creatine kinase; CRE: creatinine; GGT: γ -glutamyl transpeptidase; GLU: glucose; TBIL: total bilirubin; TG: triglycerides; TP: total protein; BUN: blood urea nitrogen; Na+: sodium; K+: potassium; Cl-: chloride.

[^11]: All values are expressed as the means (M) ± standard deviation (SD). ^\*^*p* \< 0.05, ^\*\*^*p* \< 0.01, ^\*\*\*^*p* \< 0.001. Values are compared with those of the control group. Differences were analysed by a one-way analysis of variance. ALB: total albumin; ALP: alkaline phosphatase; ALT: alanine aminotransferase; AST: aspartate aminotransferase; CHO: cholesterol; CK: creatine kinase; CRE: creatinine; GGT: γ -glutamyl transpeptidase; GLU: glucose; TBIL: total bilirubin; TG: triglycerides; TP: total protein; BUN: blood urea nitrogen; Na+: sodium; K+: potassium; Cl-: chloride.

[^12]: All values are expressed as the means (M) ± standard deviation (SD). ^\*^*p* \< 0.05, ^\*\*^*p* \< 0.01, ^\*\*\*^*p* \< 0.001. Values are compared with those of the control group. Differences were analysed by a one-way analysis of variance.

[^13]: All values are expressed as the means (M) ± standard deviation (SD). ^\*^*p* \< 0.05, ^\*\*^*p* \< 0.01, ^\*\*\*^*p* \< 0.001. Values are compared with those of the control group. Differences were analysed by a one-way analysis of variance.

[^14]: All values are expressed as the means (M) ± standard deviation (SD). ^\*^*p* \< 0.05, ^\*\*^*p* \< 0.01, ^\*\*\*^*p* \< 0.001. Values are compared with those of the control group. Differences were analysed by a one-way analysis of variance.

[^15]: All values are expressed as the means (M) ± standard deviation (SD). ^\*^*p* \< 0.05, ^\*\*^*p* \< 0.01, ^\*\*\*^*p* \< 0.001. Values are compared with those of the control group. Differences were analysed by a one-way analysis of variance.

[^16]: All values are expressed as the means (M) ± standard deviation (SD). ^\*^*p* \<0.05, ^\*\*^*p* \< 0.01, ^\*\*\*^*p* \< 0.001. Values are compared with those of the control group. Differences were analysed by a one-way analysis of variance.

[^17]: All values are expressed as the means (M) ± standard deviation (SD). ^\*^*p* \< 0.05, ^\*\*^*p* \< 0.01, ^\*\*\*^*p* \< 0.001. Values are compared with those of the control group. Differences were analysed by a one-way analysis of variance.
